[go: up one dir, main page]

TNSN99135A1 - Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression - Google Patents

Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression

Info

Publication number
TNSN99135A1
TNSN99135A1 TNTNSN99135A TNSN99135A TNSN99135A1 TN SN99135 A1 TNSN99135 A1 TN SN99135A1 TN TNSN99135 A TNTNSN99135 A TN TNSN99135A TN SN99135 A TNSN99135 A TN SN99135A TN SN99135 A1 TNSN99135 A1 TN SN99135A1
Authority
TN
Tunisia
Prior art keywords
anxiety
depression
prevention
nervous
treatment
Prior art date
Application number
TNTNSN99135A
Other languages
English (en)
Inventor
Cavazza Claudio
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of TNSN99135A1 publication Critical patent/TNSN99135A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

-UNE COMPOSITION EST I133DIVULGUEE ET H130EST DESTINEE A LA PREVENTION ET/OU AU TRAITEMENT THERAPEUTIQUE DES TROUBLES NERVEUX ET DE COMPORTEMENTS DUS AUX ETATS D'ANXIETE OU DE DEPRESSION, ET QUI PEUT PRENDRE LA FORME D'UN SUPPLEMENT DIETETIQUE, D'UN SUPPORT DIETETIQUE OU D'UN MEDICAMENT EFFECTIF, ET QUI COMPREND COMME INGREDIENTS ACTIFS CARACTERISTIQUES L'ACETYL L-CARNITINE ET L'HYPERICINE.
TNTNSN99135A 1998-06-25 1999-06-25 Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression TNSN99135A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000425A IT1299195B1 (it) 1998-06-25 1998-06-25 Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati

Publications (1)

Publication Number Publication Date
TNSN99135A1 true TNSN99135A1 (fr) 2005-11-10

Family

ID=11406010

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99135A TNSN99135A1 (fr) 1998-06-25 1999-06-25 Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression

Country Status (26)

Country Link
US (1) US6346282B1 (fr)
EP (1) EP1089744B1 (fr)
JP (1) JP2002518438A (fr)
KR (1) KR20010053059A (fr)
CN (1) CN1307479A (fr)
AT (1) ATE228369T1 (fr)
AU (1) AU756542B2 (fr)
BR (1) BR9912179A (fr)
CA (1) CA2334858C (fr)
DE (1) DE69904173T2 (fr)
DK (1) DK1089744T3 (fr)
EE (1) EE200000729A (fr)
ES (1) ES2188178T3 (fr)
HU (1) HUP0102546A3 (fr)
IL (1) IL140159A0 (fr)
IS (1) IS5765A (fr)
IT (1) IT1299195B1 (fr)
MA (1) MA26651A1 (fr)
NO (1) NO20006430L (fr)
NZ (1) NZ508882A (fr)
PL (1) PL194177B1 (fr)
PT (1) PT1089744E (fr)
SK (1) SK19302000A3 (fr)
TN (1) TNSN99135A1 (fr)
TR (1) TR200003736T2 (fr)
WO (1) WO1999066914A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
DE10015617A1 (de) * 2000-03-29 2001-10-04 Peter Laetzsch Migränemittel
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
IT1317035B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US7815894B2 (en) * 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
EP1854486A3 (fr) * 2006-03-14 2010-06-02 Wilfried P. Bieger Utilisation de dérivés de neurotransmetteurs destinée à la fabrication d'agents de traitement des perturbations neuroendocrines liées à la santé
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2344153A1 (fr) * 2008-11-11 2011-07-20 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composé utile pour le traitement de la cellulite
BRPI0900614A2 (pt) 2009-02-13 2011-06-28 Univ Fed Do Rio Grande Do Sul Ufrgs extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção
KR20130089158A (ko) * 2010-06-16 2013-08-09 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 신경 조직에서 신경발생을 증가시키기 위한 방법에 사용하기 위한 아세틸-카르니틴
ES2575995T3 (es) 2010-08-05 2016-07-04 Case Western Reserve University Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
JP2014145857A (ja) 2013-01-28 2014-08-14 Sony Corp 表示装置およびその製造方法、並びに電子機器
WO2016126169A1 (fr) * 2015-02-04 2016-08-11 Общество С Ограниченной Ответственностью "Консорциум-Пик" Procédé pour augmenter l'efficacité de la thérapie par antidépresseurs dans le cadre d'une thérapie anti-dépression et combinaison pharmaceutique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
DE4239959A1 (de) * 1992-11-27 1994-06-01 Schwabe Willmar Gmbh & Co Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia

Also Published As

Publication number Publication date
ITRM980425A0 (it) 1998-06-25
PT1089744E (pt) 2003-04-30
WO1999066914A3 (fr) 2000-04-06
DE69904173T2 (de) 2003-08-28
HUP0102546A3 (en) 2003-08-28
DE69904173D1 (de) 2003-01-09
CN1307479A (zh) 2001-08-08
IT1299195B1 (it) 2000-02-29
PL194177B1 (pl) 2007-05-31
IS5765A (is) 2000-12-08
HUP0102546A2 (hu) 2001-10-28
ITRM980425A1 (it) 1999-12-25
NZ508882A (en) 2002-06-28
DK1089744T3 (da) 2003-03-24
PL345279A1 (en) 2001-12-03
CA2334858A1 (fr) 1999-12-29
CA2334858C (fr) 2010-08-24
EP1089744B1 (fr) 2002-11-27
ES2188178T3 (es) 2003-06-16
AU4391099A (en) 2000-01-10
JP2002518438A (ja) 2002-06-25
MA26651A1 (fr) 2004-12-20
NO20006430L (no) 2001-02-21
NO20006430D0 (no) 2000-12-15
EP1089744A2 (fr) 2001-04-11
TR200003736T2 (tr) 2001-06-21
US6346282B1 (en) 2002-02-12
ATE228369T1 (de) 2002-12-15
IL140159A0 (en) 2002-02-10
SK19302000A3 (sk) 2001-09-11
KR20010053059A (ko) 2001-06-25
EE200000729A (et) 2002-06-17
BR9912179A (pt) 2001-04-10
AU756542B2 (en) 2003-01-16
WO1999066914A2 (fr) 1999-12-29

Similar Documents

Publication Publication Date Title
TNSN99135A1 (fr) Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
TNSN99163A1 (fr) COMPOSITION ANTIOXYDANTE COMPRENANT L'ACETYL-CARNITINE ET L'ACIDE α -LIPOIQUE QUI AMELIORE L'UTILISATION METABOLIQUE DU GLUCOSE
PL364174A1 (en) Fibrate-statin combinations with reduced fed-fasted effects
TNSN95046A1 (fr) Formes posologiques d'azithromycine pour le traitement d'infections microbiennes
PT918517E (pt) Composicao de microrganismos contendo acidos gordos omega-3 util como agente profilactico ou terapeutico contra a cocidiose dos animais
TNSN04191A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
CA2227977A1 (fr) Utilisation dans une composition d'un extrait d'au moins une labiee
MA27863A1 (fr) Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur
TNSN99186A1 (fr) Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques
FR2762993B1 (fr) Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
EP0699439A3 (fr) Traitement des maladies provoquées par des troubles des glandes sébacés avec l'emploi d'inhibiteurs de l'acyl CoA cholestérol acyl transferase
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
AU1870097A (en) Use of a medicament and use of mixture of substances to produce a medicament
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
FR2619713B1 (fr) Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
EP0724628A4 (fr) Modele animal transgenique pour le traitement de troubles cognitifs
TNSN00216A1 (fr) Une composition pour la prevention et/ou pour le traitement des troubles dus aux anomalies du metabolisme des lipides, comportant la propionyl l-carnitine et le chitosane
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
KR930021178A (ko) 뼈 형성을 자극하는 약제
DE59107111D1 (de) 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma
EP0820771A3 (fr) Composition pharmaceutique pour le traitement de neuropathies contenant une thiamine liposoluble et un composé de magnésium